

**Clinical trial results:****Targeted drug intervention to inhibit cancer progression in men on active surveillance for prostate cancer. Therapeutics in Active Prostate cancer Surveillance (TAPS01)****Summary**

EudraCT number	2017-001700-29
Trial protocol	GB
Global end of trial date	25 July 2019

**Results information**

Result version number	v1 (current)
This version publication date	31 July 2020
First version publication date	31 July 2020

**Trial information****Trial identification**

Sponsor protocol code	TAPS01
-----------------------	--------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03365297
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Sponsor organisation address	Box 277, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom, CB2 0QQ
Public contact	Carrie Bayliss, CCTU, +44 1223 596474, cctu@addenbrookes.nhs.uk
Scientific contact	Carrie Bayliss, CCTU, +44 1223 596474, cctu@addenbrookes.nhs.uk

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 March 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 July 2019
Global end of trial reached?	Yes
Global end of trial date	25 July 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to test if short-term use of apalutamide can reduce image defined tumour volumes in men with prostate cancer and a detectable lesion on multi-parametric MRI (mpMRI) who are being managed by Active Surveillance (AS).

Protection of trial subjects:

Drug compliance monitoring throughout treatment (self-administered therapy).

Permitted dose reductions and omissions based on presence of drug-related toxicities.

safety review every 15 days throughout treatment, using CTCAE v4.03.

Laboratory investigations to detect adverse blood results at baseline, every 30 days through treatment, and at follow up.

Trial Steering Committee safety review of trial subjects.

Quality of life assessments at baseline, every 30 days through treatment, and at follow up.

Background therapy:

N/A

Evidence for comparator:

N/A

Actual start date of recruitment	05 June 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 11
Worldwide total number of subjects	11
EEA total number of subjects	11

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	2
From 65 to 84 years	9
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

First patient first visit: 15 Jun 2018; Last Patient last visit: 25 Jul 2019. 11 patients were enrolled in total in the UK (England), of which 9 were evaluable (target: at least 8 evaluable patients and up to 10) and 2 were non-evaluable. Evaluability was as per defined in the protocol. 1 patient did not complete treatment and 1 did not start.

### Pre-assignment

Screening details:

A total of 31 patients were screened according to the eligibility criteria defined in the protocol, of which 11 were enrolled into the trial. Out of the 20 patients not enrolled, 4 patients were deemed non-eligible and 16 did not enrolled into the study due to a variety of reasons (personal, health, IMP concerns, no reason given and lost contact)

### Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Apalutamide
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Apalutamide
Investigational medicinal product code	ARN509
Other name	Erleada
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Patients were administered 240 mg (four 60 mg tablets) of apalutamide orally, once daily, for 90 consecutive days. Tablets to be swallowed whole with or without food.

Protocol allowed for one dose reduction per subject to 120 mg daily. The dose was not permitted to be re-escalated back to 240 mg daily.

A temporary break in apalutamide was acceptable in the event of a non-drug related AE. Patients were allowed to re-start apalutamide, at the previous dose, if the reason for the break had resolved within 30 days and patients did not meet the withdrawal criteria, as per defined in the study protocol. Dose modifications were also allowed for patients presenting drug-related adverse reactions, as per defined in the trial protocol (including but not limited to rash and pruritus with no rash).

Number of subjects in period 1 <sup>[1]</sup>	Apalutamide
Started	10
Completed	9
Not completed	1
Adverse event, non-fatal	1

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The baseline period accounts for extra participants that were consented but did not meet the eligibility criteria to be formally enrolled in the trial.

## Baseline characteristics

### Reporting groups

Reporting group title	Overall Period
-----------------------	----------------

Reporting group description: -

Reporting group values	Overall Period	Total	
Number of subjects	10	10	
Age categorical			
Units: Subjects			
60-69 years	4	4	
70-74 years	5	5	
75 plus years	1	1	
Age continuous			
Units: years			
arithmetic mean	70		
standard deviation	± 5	-	
Gender categorical			
Units: Subjects			
Female	0	0	
Male	10	10	
ECOG			
Units: Subjects			
No	0	0	
Yes	10	10	
ECOG performance status			
Units: Subjects			
Zero	10	10	
One	0	0	
Two	0	0	
T stage			
Units: Subjects			
T1	0	0	
T2	10	10	
Prostate cancer histology			
Units: Subjects			
Adenocarcinoma	10	10	
Other	0	0	
Gleason Grade: Grade X:			
Units: Subjects			
Gleason sum 6	10	10	
Gleason =7	0	0	
Gleason >=8	0	0	
Gleason Grade: Grade Y			
Units: Subjects			
Gleason sum 6	10	10	
Gleason =7	0	0	
Gleason >=8	0	0	

Height (cm): Units: cm arithmetic mean standard deviation	173 ± 6	-	
Weight Units: Kg arithmetic mean standard deviation	78.4 ± 8.6	-	
Pulse Units: beats/min arithmetic mean standard deviation	71 ± 15	-	
Systolic blood pressure Units: mmHg arithmetic mean standard deviation	139 ± 12	-	
Diastolic blood pressure Units: mmHg arithmetic mean standard deviation	80 ± 6	-	
Temperature Units: Degress celcius arithmetic mean standard deviation	36.6 ± 0.3	-	

## End points

### End points reporting groups

Reporting group title	Apalutamide
Reporting group description: -	

### Primary: Percentage change in tumour size measured by mpMRI (tumour volume - cm<sup>3</sup>)

End point title	Percentage change in tumour size measured by mpMRI (tumour volume - cm <sup>3</sup> ) <sup>[1]</sup>
-----------------	--

End point description:

Percentage change in tumour size measured by mpMRI (tumour volume<sup>3</sup>) or absence of a lesion between baseline and day 90. The percentage of patients achieving tumour downsizing with their 95% confidence interval was estimated using the primary lesion (i.e. the largest lesion if a patient had more than one lesion).

End point type	Primary
----------------	---------

End point timeframe:

Tumour volume (cm<sup>3</sup>) change from baseline at day 90.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: It's a single arm study.

<b>End point values</b>	Apalutamide			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: tumour volume (cm <sup>3</sup> )				
arithmetic mean (standard deviation)				
Percentage change	51.86 (± 17.1)			

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Change in total tumour volume

End point title	Change in total tumour volume
-----------------	-------------------------------

End point description:

Percentage change in total tumour size measured by mpMRI (tumour volume<sup>3</sup>) or absence of a lesion between baseline and day 90.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Percentage change from baseline at day 90

<b>End point values</b>	Apalutamide			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: total tumour volume - cm <sup>3</sup>				
arithmetic mean (standard deviation)	52.4 (± 17.4)			

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Change in gland volume

End point title	Change in gland volume
-----------------	------------------------

End point description:

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Gland volume (cm<sup>3</sup>) change from baseline at day 90

<b>End point values</b>	Apalutamide			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Gland volume in cm <sup>3</sup>				
arithmetic mean (standard deviation)	36.2 (± 8.7)			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	Treatment
-----------------------	-----------

Reporting group description: -

<b>Serious adverse events</b>	Treatment		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 10 (10.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Investigations			
Neutrophil Count Decreased	Additional description: Neutrophil Count Decreased		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Treatment		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)		
Vascular disorders			
Hot flashes	Additional description: Hot flashes		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Hypertension	Additional description: Hypertension		
subjects affected / exposed	3 / 10 (30.00%)		
occurrences (all)	4		

General disorders and administration site conditions			
Fatigue	Additional description: Fatigue		
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	6		
Flu like symptoms	Additional description: Flu like symptoms		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Nipple tenderness	Additional description: Nipple tenderness		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Non-cardiac chest pain	Additional description: Non-cardiac chest pain		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Pain	Additional description: Pain		
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Reproductive system and breast disorders			
Breast pain	Additional description: Breast pain		
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	4		
Erectile Dysfunction	Additional description: Erectile Dysfunction		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Laryngeal inflammation	Additional description: Laryngeal inflammation		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Psychiatric disorders			
Anxiety	Additional description: Anxiety		
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Libido decreased	Additional description: Libido decreased		
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Investigations			

Alanine aminotransferase increased subjects affected / exposed occurrences (all)	Additional description: Alanine aminotransferase increased	
	6 / 10 (60.00%) 6	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	Additional description: Aspartate aminotransferase increased	
	3 / 10 (30.00%) 3	
Lymphocyte count decreased subjects affected / exposed occurrences (all)	Additional description: Lymphocyte count decreased	
	4 / 10 (40.00%) 8	
Serum amylase increased subjects affected / exposed occurrences (all)	Additional description: Serum amylase increased	
	1 / 10 (10.00%) 1	
White Blood Cell Decreased subjects affected / exposed occurrences (all)	Additional description: White Blood Cell Decreased	
	1 / 10 (10.00%) 1	
Nervous system disorders		
Dizziness subjects affected / exposed occurrences (all)	Additional description: Dizziness	
	1 / 10 (10.00%) 1	
Dysgeusia subjects affected / exposed occurrences (all)	Additional description: Dysgeusia	
	1 / 10 (10.00%) 1	
Headache subjects affected / exposed occurrences (all)	Additional description: Headache	
	1 / 10 (10.00%) 1	
Blood and lymphatic system disorders		
Anemia subjects affected / exposed occurrences (all)	Additional description: Anemia	
	2 / 10 (20.00%) 2	
Ear and labyrinth disorders		
Vertigo subjects affected / exposed occurrences (all)	Additional description: Vertigo	
	1 / 10 (10.00%) 2	
Gastrointestinal disorders		
Abdominal Pain	Additional description: Abdominal Pain	

subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Dyspepsia	Additional description: Dyspepsia		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Vomiting	Additional description: Vomiting		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Skin and subcutaneous tissue disorders			
Pruritus	Additional description: Pruritus		
subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3		
Rash maculo-papular	Additional description: Rash maculo-papular		
subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 5		
Renal and urinary disorders			
Cystitis Noninfective (Nocturia)	Additional description: Cystitis Noninfective (Nocturia)		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Cystitis noninfective (Dysuria)	Additional description: Cystitis noninfective (Dysuria)		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Proteinuria	Additional description: Proteinuria		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Renal and urinary disorders - Other,	Additional description: Renal and urinary disorders - Other,		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Urinary Frequency	Additional description: Urinary Frequency		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2		
Urinary Tract Pain	Additional description: Urinary Tract Pain		
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Endocrine disorders			

Hyperthyroidism subjects affected / exposed occurrences (all)	Additional description: Hyperthyroidism		
	1 / 10 (10.00%) 1		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	Additional description: Arthralgia		
	1 / 10 (10.00%) 1		
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Upper respiratory tract infection		
	1 / 10 (10.00%) 1		
Metabolism and nutrition disorders Hypertriglyceridemia subjects affected / exposed occurrences (all)	Additional description: Hypertriglyceridemia		
	8 / 10 (80.00%) 10		
Metabolism and nutrition disorders subjects affected / exposed occurrences (all)	Additional description: Metabolism and nutrition disorders		
	1 / 10 (10.00%) 1		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported